Javascript must be enabled to continue!
Efficacy and Safety of Traditional Chinese Medicine (Lianhua Qingwen) for Coronavirus Disease 2019: a Systematic Review and Meta-analysis
View through CrossRef
Abstract
Background: The coronavirus disease 2019(COVID-19) had become an epidemic and spread across the world, lead to severe respiratory failure and death. Traditional Chinese Medicine(TCM), Such as Lianhua Qingwen has been widely used in the prevention and treatment of COVID-19, This systematic review and meta-analysis will assess the effects of traditional Chinese herbal medicine(Lianhua Qingwen) in COVID-19 pneumonia from the randomized controlled trials(RCTs) and case control studies(CCSs).Method: we search the literatures in databases inculding PubMed, Embase, Web of science, Cochrane Library, Wanfang, Chinese Science and Technology Periodical Database (VIP), Chinese Biomedical Literature Database (CBM) and China National Knowledge Infrastructure(CNKI), setting the date from December 1, 2019, to June 1, 2021, Cochrane Risk of Bias tool and the Newcastle-Ottawa Scale were used to assess the quality of randomized controlled trials. All analyses were conducted by Stata 14.0.Results: nine studies with 1163 patients(616males) were included, six were RCTs, three are CCSs. Compared with patients treated by western medicine alone, patients treated by Lianhua Qingwen combined with western medicine have a higher overall effective rate[RR=1.20, 95%CI1.20(1.11, 1.31), P=0.000], cardinal symptom disappearance rate[disappearance rate of fever: OR:3.64, 95%CI(1.57, 8.47), P=0.001;disappearance rate of cough: OR:1.97, 95%CI(1.45, 2.68), P=0.001; disappearance rate of fatigue: OR:2.55, 95%CI(1.09, 5.99), P=0.032] and CT recovery rate[RR:1.25, 95%CI(1.13,1.38), P=0.000], reduce the rate of the progress into severe diseases of COVID-19 patients[RR:0.43, 95%CI(0.30, 0.62), P=0.000], with more shorter duration of fever[WMD=-1.07,95%CI(-1.77, -0.37), P=0.003], The including studies described that Lianhua Qingwen did not increase the adverse drug reactions.Conclusion: Lianhua Qingwen may have advantages in improving the clinical effective rate and cardinal symptom disappearance rate. Besides, it also had an excellent effect on the improvement of the chest CT and the proportion reducing of progress into severe clinical disease, which could be used as an effective therapy for COVID-19.
Title: Efficacy and Safety of Traditional Chinese Medicine (Lianhua Qingwen) for Coronavirus Disease 2019: a Systematic Review and Meta-analysis
Description:
Abstract
Background: The coronavirus disease 2019(COVID-19) had become an epidemic and spread across the world, lead to severe respiratory failure and death.
Traditional Chinese Medicine(TCM), Such as Lianhua Qingwen has been widely used in the prevention and treatment of COVID-19, This systematic review and meta-analysis will assess the effects of traditional Chinese herbal medicine(Lianhua Qingwen) in COVID-19 pneumonia from the randomized controlled trials(RCTs) and case control studies(CCSs).
Method: we search the literatures in databases inculding PubMed, Embase, Web of science, Cochrane Library, Wanfang, Chinese Science and Technology Periodical Database (VIP), Chinese Biomedical Literature Database (CBM) and China National Knowledge Infrastructure(CNKI), setting the date from December 1, 2019, to June 1, 2021, Cochrane Risk of Bias tool and the Newcastle-Ottawa Scale were used to assess the quality of randomized controlled trials.
All analyses were conducted by Stata 14.
Results: nine studies with 1163 patients(616males) were included, six were RCTs, three are CCSs.
Compared with patients treated by western medicine alone, patients treated by Lianhua Qingwen combined with western medicine have a higher overall effective rate[RR=1.
20, 95%CI1.
20(1.
11, 1.
31), P=0.
000], cardinal symptom disappearance rate[disappearance rate of fever: OR:3.
64, 95%CI(1.
57, 8.
47), P=0.
001;disappearance rate of cough: OR:1.
97, 95%CI(1.
45, 2.
68), P=0.
001; disappearance rate of fatigue: OR:2.
55, 95%CI(1.
09, 5.
99), P=0.
032] and CT recovery rate[RR:1.
25, 95%CI(1.
13,1.
38), P=0.
000], reduce the rate of the progress into severe diseases of COVID-19 patients[RR:0.
43, 95%CI(0.
30, 0.
62), P=0.
000], with more shorter duration of fever[WMD=-1.
07,95%CI(-1.
77, -0.
37), P=0.
003], The including studies described that Lianhua Qingwen did not increase the adverse drug reactions.
Conclusion: Lianhua Qingwen may have advantages in improving the clinical effective rate and cardinal symptom disappearance rate.
Besides, it also had an excellent effect on the improvement of the chest CT and the proportion reducing of progress into severe clinical disease, which could be used as an effective therapy for COVID-19.
Related Results
Lianhua‐Qingwen Displays Antiviral and Anti‐Inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model
Lianhua‐Qingwen Displays Antiviral and Anti‐Inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model
Influenza B virus (IBV) is one of the main pathogens of the annual influenza epidemic, and the disease burden is significant, especially among children and young teenagers. In this...
Integrated Lianhua-Qingwen and Western Medicine Versus Western Medicine-Only Therapies Against COVID-19: A Systematic Review and Meta-Analysis
Integrated Lianhua-Qingwen and Western Medicine Versus Western Medicine-Only Therapies Against COVID-19: A Systematic Review and Meta-Analysis
Abstract
Background
Coronavirus disease 2019 (COVID-19) is an acute respiratory infectious disease caused by severe acute respiratory syndrome, has resulted in a global ou...
Combination of Chinese and Western Medicine: Molnupiravir and Lianhua Qingwen in the Treatment of Novel Coronavirus Pneumonia (COVID-19)
Combination of Chinese and Western Medicine: Molnupiravir and Lianhua Qingwen in the Treatment of Novel Coronavirus Pneumonia (COVID-19)
Abstract
Objective: This study aimed to assess the effectiveness of Molnupiravir and Lianhua Qingwen in treating patients with novel coronavirus pneumonia (COVID-19).
Metho...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
WITHDRAWN: Elucidating the Mechanisms of Action of Lianhua Qingwen decoction for the Treatment of COVID-19 via Systems Pharmacology Approaches
WITHDRAWN: Elucidating the Mechanisms of Action of Lianhua Qingwen decoction for the Treatment of COVID-19 via Systems Pharmacology Approaches
Abstract
Due to the severity of the COVID-19 epidemic, to identify a proper treatment for COVID-19 is of great significance. Traditional Chinese Medicine (TCM) has ...
Efficacy and Safety of Chinese Medicine Lianhua Qingwen for Treating COVID-19: An Updated meta-Analysis
Efficacy and Safety of Chinese Medicine Lianhua Qingwen for Treating COVID-19: An Updated meta-Analysis
The traditional Chinese medicine formula Lianhua Qingwen (LQ) combined with western medicine therapy is beneficial to coronavirus disease-19 (COVID-19), but there is still a lack o...
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus , is causing a serious worldwide COVID-19 pandemic. The emergence of strains with rapid spread and...

